Aktis Oncology, Inc. Annual Report: A Summary for Investors

I’ve put together this guide to help you understand how Aktis Oncology performed this year. My goal is to break down their complex filings into simple terms so you can decide if this company fits your investment goals.

1. What does this company do?

Aktis Oncology is a biotech company developing a new class of cancer treatments called "miniprotein radioconjugates." These molecules are smaller than traditional antibodies. Because they are small, they penetrate tumors faster and clear from the bloodstream quickly, which protects healthy organs from radiation.

Their lead drug, [225Ac]Ac-AKY-1189, targets Nectin-4, a protein found in bladder, breast, and lung cancers. It uses Actinium-225, a powerful radioactive isotope, to deliver high-energy radiation directly to tumor cells, breaking their DNA.

2. Financial performance: Are they making money?

No. Aktis is in the early stages of development and has no product sales. They are currently losing money as they invest heavily in research and development.

The company spends about $85 million to $100 million per year. This money goes toward clinical trials, drug development, and building specialized manufacturing facilities. They rely on venture capital and partnerships to fund their operations until they can sell a product or get acquired.

3. Major wins and progress

The FDA recently cleared the company to begin human clinical trials for their lead drug. This Phase 1b trial is testing the drug’s safety and effectiveness in patients. Aktis expects to share initial results in early 2027.

To prepare, they are building a manufacturing facility in North Carolina. They are also signing agreements with global isotope producers to ensure they have a steady supply of Actinium-225.

4. Financial health and risks

This is a high-risk, high-reward investment. Here is what you should know:

• Cash Runway: The company has enough cash to last until late 2025 or early 2026. They will likely need to issue more shares—which reduces your ownership percentage—or find new partners within the next 18 months to keep the lights on.
• Manufacturing Hurdles: Their drugs have very short shelf lives and require "just-in-time" delivery. Any manufacturing errors or supply shortages of radioactive isotopes could delay their clinical trials.
• Intellectual Property: While they own patents for their drug technology, they do not control the supply of the radioactive isotopes they need.
• Competition: A drug called Padcev already dominates the Nectin-4 market, generating $1.9 billion in 2024. Aktis must prove their treatment is safer or more effective than what is already available.

5. Future outlook

Aktis wants to be a platform company, not just a one-drug developer. They plan to use their technology to create a pipeline of different cancer treatments. Their value depends almost entirely on the 2027 clinical trial results. Success hinges on proving their drugs can kill tumors safely while allowing for repeat doses.

---

Investor Takeaway: Aktis Oncology is a classic "all-or-nothing" biotech play. Because they have no revenue and are years away from a potential product launch, your investment is essentially a bet on the 2027 clinical trial data. If you are comfortable with the risks of early-stage drug development and the potential for share dilution, the company’s platform approach offers a unique way to gain exposure to the growing field of radiopharmaceuticals.